Vendor comparison · 2026
MOTS-c vendors: 31 compared on COAs and price
MetabolicAlso known as Mitochondrial-derived peptide MOTS-c
Evidence tier
Multiple human trials
2 human trials · 2 observational
- Vendors carrying it
- 31
- 28 with a listed price
- Vendors with checkable COAs
- 16
- 18 publish any certificate
- Lots tested
- 31
- 27 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- 24 Sept 2026
- oldest 4 Feb 2026
- Laboratories named
- 10
- most often Freedom Diagnostics Testing
- Median label gap
- 5.5%
- 48% of lots within 5% of label
- Median purity
- 99.80%
- 29 of 31 lots at 99% or above
- Lowest price per mg
- $2.00
- peer median $5.50
- Publications located
- 247
- researched since 2015
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
Featured in the October 2026 peptide COA report →
PeptidePlugs has the most checkable MOTS-c testing in this index: 4 lots assayed by Freedom Diagnostics Testing, the newest on 19 Aug 2026. The lowest listed price is $2.00 per mg at Next Gen Peptides, against a peer median of $5.50. 31 vendors carrying MOTS-c are compared below. 16 publish at least one certificate naming a checkable laboratory, 31 lot records are on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying MOTS-c
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Origin LabsISO/IEC 17025 | 96.9100% | — | 2 / 2 | Freedom Diagnostics Testing | 99.6% | 24.3% | ||
| 2 | Next Gen PeptidesISO/IEC 17025 | 93.697% | $2.00 (36%) | 3 / 3 | ILS Laboratories | 99.6% | 4.1% | ||
| 3 | PeptidePlugs | 91.394% | $3.00 (55%) | 4 / 4 | Freedom Diagnostics Testing | 99.7% | 7.1% | ||
| 4 | Amino ClubISO/IEC 17025Age-gated COAs | 9198% | $4.00 (73%) | 1 / 1 | Freedom Diagnostics Testing | 99.8% | 10.5% | ||
| 5 | Ascend ScienceISO/IEC 17025 | 89.994% | $4.55 (83%) | 3 / 3 | ILS Laboratories, Kovera Labs and/or ILS Labs | 99.9% | 7.0% | ||
| 6 | Hydro Research PeptidesISO/IEC 17025 | 85.689% | $3.00 (55%) | 1 / 1 | ILS Laboratories | 99.7% | 0.0% | ||
| 7 | Modern AminosISO/IEC 17025COAs need an account | 85.697% | $4.20 (76%) | 2 / 2 | Freedom Diagnostics Testing | 99.8% | 8.3% | ||
| 8 | NeuroLabs Research | 84.491% | $4.50 (82%) | 0 | — | — | — | — | no reportVisit site |
| 9 | Bench Grade Peptides | 83.689% | $4.70 (86%) | 2 / 2 | AV Analytics | 99.8% | 1.3% | ||
| 10 | Simple Peptide | 83.592% | $4.30 (78%) | 1 / 1 | Freedom Diagnostics Testing | 99.8% | 10.6% | ||
| 11 | Stealth Research Labs | 82.191% | $5.50 (100%) | 1 / 1 | Bioviridian Inc. | 99.8% | 1.6% | ||
| 12 | One Aminos | 8089% | $6.00 (109%) | 1 / 1 | United Laboratories | 99.8% | 10.3% | ||
| 13 | Ascension Peptides | 78.989% | $6.20 (113%) | 1 / 1 | MZ Biolabs | 99.7% | 5.8% | ||
| 14 | CuroISO/IEC 17025 | 78.897% | $6.90 (126%) | 1 / 1 | BTLabs | 99.9% | 5.0% | ||
| 15 | Evo Labs Research | 77.887% | $4.00 (73%) | 0 | — | — | — | — | no reportVisit site |
| 16 | Koi PeptidesAge-gated COAs | 76.492% | $5.50 (100%) | 0 | — | — | — | — | no reportVisit site |
| 17 | Protide HealthAge-gated COAs | 74.592% | $6.50 (118%) | 0 | — | — | — | — | no reportVisit site |
| 18 | Prime PeptidesISO/IEC 17025 | 73.996% | $6.00 (109%) | 0 | — | — | — | — | no reportVisit site |
| 19 | Good Science Bio | 71.171% | $4.50 (82%) | 0 | — | — | — | — | no reportVisit site |
| 20 | Northline LabsISO/IEC 17025 | 70.695% | $8.50 (155%) | 2 / 2 | ILS Laboratories | 99.7% | 1.8% | ||
| 21 | Eternal Peptides | 6963% | $3.00 (55%) | 0 | — | — | — | — | no reportVisit site |
| 22 | BioLongevity Labs | 67.572% | $5.50 (100%) | 0 | — | — | — | — | no reportVisit site |
| 23 | Licensed Peptides | 65.687% | $7.70 (140%) | 0 | — | — | — | — | no reportVisit site |
| 24 | Evolve Peptides | 63.668% | $6.00 (109%) | 0 | — | — | — | — | no reportVisit site |
| 25 | Mile High Compounds | 63.591% | $4.67 (85%) | 0 / 3 | Not named | 98.9% | 5.1% | ||
| 26 | True Research Labs | 62.568% | $5.90 (107%) | 0 | — | — | — | — | no reportVisit site |
| 27 | Vial Drop Labs | 59.474% | — | 1 / 1 | KMD Analytical (KMD Group LLC) | 98.4% | 0.0% | ||
| 28 | Improved Peptides | 58.487% | $7.90 (144%) | 0 / 1 | Not named | 99.0% | 6.5% | ||
| 29 | Vertex Labs | 56.172% | — | 1 / 1 | Freedom Diagnostics Testing | 99.8% | 7.9% | ||
| 30 | GenX Peptides | 53.169% | $9.00 (164%) | 0 | — | — | — | — | no reportVisit site |
| 31 | Biotech Peptides | 49.160% | $9.90 (180%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of MOTS-c is on file. All 31 records below were published by the vendor that sells the product, naming the laboratory shown. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
What the certificates show
29 of 31 lots at 99% or above; median 99.80%.
| Range | lots |
|---|---|
| <95% | 0 |
| 95–97% | 0 |
| 97–98% | 0 |
| 98–99% | 2 |
| 99–99.5% | 6 |
| ≥99.5% | 23 |
48% of lots within 5% of the labelled mass; median gap 5.5%.
| Range | lots |
|---|---|
| ≤2% | 9 |
| 2–5% | 5 |
| 5–10% | 7 |
| 10–20% | 8 |
| >20% | 2 |
28 vendors, $2.00 to $9.90; median $5.50.
| Range | vendors |
|---|---|
| $2.00–$4.00 | 4 |
| $4.00–$6.00 | 13 |
| $6.00–$8.00 | 8 |
| $8.00–$10.00 | 3 |
Purity and mass are read from each certificate as published; the label gap is |labeled − assayed| ÷ labeled. Every value behind these bars is in the certificate table below.
Laboratories used
| Laboratory | Lots | Vendors | Share | Verify |
|---|---|---|---|---|
| Freedom Diagnostics TestingUS | 11 | 6 | 35% | Public lookup |
| ILS LaboratoriesUS | 7 | 4 | 23% | Public lookup |
| AV Analytics | 2 | 1 | 6% | No public lookup found |
| Bioviridian Inc.US | 1 | 1 | 3% | Public lookup |
| BTLabs | 1 | 1 | 3% | No public lookup found |
| KMD Analytical (KMD Group LLC)US | 1 | 1 | 3% | Public lookup |
| Kovera Labs | 1 | 1 | 3% | No public lookup found |
| Kovera Labs and/or ILS Labs | 1 | 1 | 3% | No public lookup found |
| MZ BiolabsUS | 1 | 1 | 3% | No public lookup found |
| United LaboratoriesIN | 1 | 1 | 3% | Public lookup |
4 further records nameno checkable laboratory (a placeholder, a signature line or the vendor’s own name). They are listed in the certificate table but not counted as third-party testing.
Every certificate record
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2015 — 11 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
247 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.6% across 31 certificates
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
±0.41 pts purity across lots, mean label deviation 6.7%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
31 of 31 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
27 of 31 certificates from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is MOTS-c?
A mitochondrial-derived peptide studied for roles in cellular metabolism, insulin sensitivity and exercise physiology.
Studied in published research for metabolism, insulin sensitivity and exercise capacity.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Published work is largely preclinical, in cell and animal models of metabolism. PepIndex does not evaluate clinical significance and does not describe administration.
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation — Frontiers in endocrinology (2023)
Peer-reviewed article indexed in PubMed, published in Frontiers in endocrinology (2023).
- MOTS-c Functionally Prevents Metabolic Disorders — Metabolites (2023)
Peer-reviewed article indexed in PubMed, published in Metabolites (2023).
- The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance — Cell metabolism (2015)
Peer-reviewed article indexed in PubMed, published in Cell metabolism (2015).
- MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus — BioEssays : news and reviews in molecular, cellular and developmental biology (2019)
Peer-reviewed article indexed in PubMed, published in BioEssays : news and reviews in molecular, cellular and developmental biology (2019).
- Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination — Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024)
Peer-reviewed article indexed in PubMed, published in Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024).
- MOTS-c: A potential anti-pulmonary fibrosis factor derived by mitochondria — Mitochondrion (2023)
Peer-reviewed article indexed in PubMed, published in Mitochondrion (2023).
- The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus — Pharmacological research (2022)
Peer-reviewed article indexed in PubMed, published in Pharmacological research (2022).
- MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes — Redox biology (2025)
Peer-reviewed article indexed in PubMed, published in Redox biology (2025).
Indexed studies4 human-evidence of 4
- Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Neurohumoral and Mitochondrial Activation in Patients With Diabetes — Human — observational, 2025
We investigated the effects of the combined treatment with glucagon like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on NT-proBNP (N-terminal pro-brain natriuretic peptide), GDF-15 (growth differentiation factor 15), and MOTS-c (mitochondrial-derived peptide-c) in patients with type 2 diabetes (T2D) and high or very high cardiovascular risk. We studied 163 consecutive patients with type 2 diabetes who were treated with insulin…
- Circulating levels of MOTS-c in patients with breast cancer treated with metformin — Human — controlled trial, 2022
The mitokine MOTS-c is a mitochondrially-encoded "exercise-mimetic peptide" expressed in multiple tissues, particularly skeletal muscles, which can be detected as a circulating hormone in the blood. MOTS-c mechanisms of action (MoA) involve insulin sensitization, enhanced glucose utilization, suppression of mitochondrial respiration, and targeting of the folate-AICAR-AMPK pathway. Although MOTS-c MoA largely overlap those of the anti-diabetic biguanide metformin, the putative…
- Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization — Human — controlled trial, 2025
Heat stress, like exercise, can elicit beneficial mitochondrial adaptations and attenuate disuse muscle atrophy. The beneficial effects of heat therapy may in part be related to mitokines as they are released by the cells in response to perceived mitochondrial stress. This study thus investigated the effect of repeated heat exposures on mitokine response in the context of immobilization-induced muscle atrophy. A total of 19 physically active men underwent 4 wk of supervised t…
- Impact of Radiation Therapy on Serum Humanin and MOTS-c Levels in Patients with Lung or Breast Cancer — Human — observational, 2024
Lung and breast cancer are the most frequent causes of death from cancer globally. The objectives of this research were to evaluate the serum mitochondrial open reading frame of the 12S rRNA-c (MOTS-c) and humanin levels in lung or breast cancer patients, and investigate the impacts of radiation therapy on the circulating levels of these peptides. 35 lung cancer patients, 34 breast cancer patients, and healthy volunteers as a control group were recruited in this prospective o…
Evidence digest
What the research on MOTS-c actually shows
The indexed literature on MOTS-c includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether MOTS-c is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
3 things the literature does not establish →
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.